×
About 2,611 results

ALLMedicine™ Hemophilia B Center

Research & Reviews  1,069 results

First open-label, single-arm, prospective study of real-world use of FIX replacement th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154445
Medicine Yang R, Wu R et. al.

May 25th, 2021 - Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement ...

Identification of Zebrafish Ortholog for Human Coagulation Factor IX and its Age-depend...
https://doi.org/10.1111/jth.15365
Journal of Thrombosis and Haemostasis : JTH; Iyer N, Al Qaryoute A et. al.

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

Identification of a modified coagulation factor X with enhanced activation properties a...
https://doi.org/10.1016/j.bcmd.2021.102570
Blood Cells, Molecules & Diseases; Ebert M, Raquet E et. al.

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

The Cost-effectiveness of Gene Therapy for Severe Hemophilia B: Microsimulation Study f...
https://doi.org/10.1182/blood.2021010864
Blood Bolous NS, Chen Y et. al.

Apr 25th, 2021 - Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. While multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been pu...

Health care resource utilization and cost burden of hemophilia B in the United States.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045501
Blood Advances; Buckner TW, Bocharova I et. al.

Apr 8th, 2021 - Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associate...

see more →

Guidelines  43 results

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
https://onlinelibrary.wiley.com/doi/10.1111/hae.14139
Haemophilia Shapiro AD

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

The role of total ankle replacement in patients with hemophilia and end‐stage ankle arthropathy: A review
https://onlinelibrary.wiley.com/doi/10.1111/hae.14196
Haemophilia Sackstein P

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 20...

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline
http://www.ukhcdo.org/wp-content/uploads/2017/03/Guidelines-for-the-management-of-acute-joint-bleeds-and-chronic-synovitis-in-haemophilia.pdf
Haemophilia

Jan 23rd, 2017 - Prior to the availability of clotting factor concentrates, the natural history of arthropathy in severe haemophilia was well described, with recurrent bleeds into joints leading to progressive joint damage and ultimate destruction with associa...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  1,191 results

First open-label, single-arm, prospective study of real-world use of FIX replacement th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154445
Medicine Yang R, Wu R et. al.

May 25th, 2021 - Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement ...

Identification of Zebrafish Ortholog for Human Coagulation Factor IX and its Age-depend...
https://doi.org/10.1111/jth.15365
Journal of Thrombosis and Haemostasis : JTH; Iyer N, Al Qaryoute A et. al.

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

Health Costs Over 25 Times Higher for Patients With Hemophilia B
https://www.medscape.com/viewarticle/951014

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Identification of a modified coagulation factor X with enhanced activation properties a...
https://doi.org/10.1016/j.bcmd.2021.102570
Blood Cells, Molecules & Diseases; Ebert M, Raquet E et. al.

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

The Cost-effectiveness of Gene Therapy for Severe Hemophilia B: Microsimulation Study f...
https://doi.org/10.1182/blood.2021010864
Blood Bolous NS, Chen Y et. al.

Apr 25th, 2021 - Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. While multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been pu...

see more →

News  277 results

Health Costs Over 25 Times Higher for Patients With Hemophilia B
https://www.medscape.com/viewarticle/951014

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Gene Therapy a Potential 'Game Changer' for Hemophilia B
https://www.medscape.com/viewarticle/942762

Dec 17th, 2020 - NEW YORK (Reuters Health) - An investigational gene therapy for hemophilia B substantially increased production of the blood-clotting protein factor IX and reduced the number of bleeding episodes and need for prophylactic therapy in a phase-3 tria...

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
https://onlinelibrary.wiley.com/doi/10.1111/hae.14139
Haemophilia Shapiro AD

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

The role of total ankle replacement in patients with hemophilia and end‐stage ankle arthropathy: A review
https://onlinelibrary.wiley.com/doi/10.1111/hae.14196
Haemophilia Sackstein P

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102_2

Oct 21st, 2020 - Hemophilia A is an inherited deficiency of FVIII and an X-linked recessive disorder. Hemophilia B, another recessive disorder, is characterized by a deficiency in factor IX. Hemophilia C is an autosomal recessive disorder in which patients are def...

see more →